



# Tumor Markers: Order Confidently with LifeLabs

Tumor markers found in blood samples help monitor cancer progression, assess treatment response, and detect recurrence. LifeLabs offers comprehensive tumor marker testing across multiple cancer types, supporting every stage of your clinical decision making.



**Consistent Results. Confident Decisions.**

Our extensive network of collection centers ensures your patients can complete testing conveniently with LifeLabs every time, delivering the accurate trend interpretation you need to guide treatment without gaps or delays. Through MyVisit™, one of our lab technicians can even meet your patient in-home or at a location of their choice.

## Serum Free Light Chains (sFLC)

**Test Use:** Plays a critical role in diagnosis and monitoring of multiple myeloma and related plasma cell disorders.

sFLC measures free kappa and lambda light chains in the blood. Abnormal levels are associated with plasma cell disorders such as multiple myeloma and AL amyloidosis. This test is useful for patients with suspected monoclonal gammopathies, providing insight into clonal activity and disease burden.<sup>1,2</sup>

The International Myeloma Working Group recommends sFLC for diagnostic screening for myeloma in combination with serum immunoelectrophoresis and serum protein electrophoresis.<sup>3,13</sup>

## Chromogranin A (CgA)

**Test Use:** Detect, monitor, and manage neuroendocrine tumors (NETs)

CgA is a protein released by neuroendocrine cells. Elevated levels can indicate NETs, including in the gastrointestinal tract and pancreas. Testing supports diagnosis, staging, and monitoring, especially in patients presenting with nonspecific symptoms.<sup>4,5</sup>

## Cancer Antigen 125 (CA125)

**Test Use:** Management of gynecological cancers, including ovarian and uterine.

CA125 is a high-molecular-weight glycoprotein. Measurement is used to support diagnosis in symptomatic patients, assess treatment response, and monitor for recurrence. Sustained or rising levels can prompt further imaging or clinical evaluation.<sup>6,7</sup>

## Carbohydrate Antigen 19-9 (CA19-9)


**Test Use:** Management of pancreatic cancer and gastrointestinal malignancies.

CA19-9 is a carbohydrate antigen associated with pancreatic, biliary, and gastrointestinal malignancies. Measurement is valuable for monitoring disease progression and treatment response.<sup>8,9</sup>

## Cancer Antigen 15-3 (CA 15-3)






**Test Use:** Management of breast cancer.


CA15-3 is a marker often elevated in breast cancer, particularly in metastatic disease. It is used primarily to monitor therapy effectiveness and detect recurrence. Levels should be interpreted in conjunction with imaging and clinical findings.<sup>10,11</sup>

 Elevated tumor marker levels may indicate cancer activity, and are interpreted alongside imaging, pathology, and clinical findings rather than used alone for diagnosis. Levels may be elevated in non-cancerous conditions, trends over time are often more meaningful than a single measurement, and testing decisions should always be guided by a qualified healthcare professional.

## Transforming the patient journey with tumor marker testing

Lifelabs is proud to offer one of the most comprehensive cancer testing portfolios in the industry, ensuring you have the insights you need to facilitate informed decision making.

Test name	Turnaround time from sample receipt at Lifelabs	Specimen type
Serum Free Light Chains (sFLC)	10 days	 Blood
Chromogranin A (CgA)	10 days	 Blood
Cancer Antigen 125 (CA 125)	24 hours	 Blood
Carbohydrate Antigen 19-9 (CA19-9)	24 hours	 Blood
Cancer Antigen 15-3 (CA 15-3)	5 days	 Blood

 For more information on these tests, including detailed collection and transport requirements, visit [tests.lifelabs.com/s/](https://tests.lifelabs.com/s/)

As an industry leader, we're committed to advancing the science behind cancer testing.

Discover LifeLabs Cancer Tests at [lifelabs.com/oncology](https://lifelabs.com/oncology)



### Hereditary Cancer Panel

Understand your patients' genetic risk. Includes full sequencing and analysis of 84 of the most common genes linked to hereditary cancers, including breast, ovarian, colorectal, and more.



### Signatera™

Monitor cancer treatment with precision and detect recurrence months earlier than traditional imaging.

#### References

1. Drayson MT, Tang LX, Drew R, Mead GP, Carr-Smith HD, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. *Blood*. 2001;97(9):2900-2902. doi:10.1182/blood.V97.9.2900
2. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. *Clin Chem*. 2002;48(9):1437-1444. doi:10.1093/clinchem/48.9.1437
3. *Lancet Oncology* 2014 Nov; 15(12): e538-48
4. Modlin JM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A—biological function and clinical utility in neuroendocrine tumor disease. *Ann Surg Oncol*. 2010;17(9):2427-2443. doi:10.1245/s10434-010-1006-3
5. Kidd M, Bodei L, Modlin JM. Chromogranin A: any relevance in neuroendocrine tumors? *Curr Opin Endocrinol Diabetes Obes*. 2016;23(1):28-37. doi:10.1097/MED.0000000000000215
6. Charkhchi P, Cybulski C, Gronwald J, et al. CA125 and ovarian cancer: a comprehensive review. *Cancers (Basel)*. 2020;12(12):3730. doi:10.3390/cancers12123730
7. Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. *Cancer*. 2009;115(12):2250-2252. doi:10.1002/cncr.25203
8. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. *Am J Gastroenterol*. 1990;85(4):350-355. PMID:2183589.
9. Balleshaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence-based appraisal. *J Gastrointest Oncol*. 2012;3(2):105-119. doi:10.3978/j.issn.2078-6891.2011.021
10. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol*. 2007;25(33):5287-5312. doi:10.1200/JCO.2007.14.2364
11. Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. *Med Princ Pract*. 2012;22(1):4-11. doi:10.1159/000338393
12. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2024;99(9):1802-1824. doi:10.1002/ajh.27422
13. Bergstrom DJ, Kotb R, Louzada ML, Sutherland HJ, Tavoularis S, Venner CP, et al. Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. *Clin Lymphoma Myeloma Leuk*. 2020;20(7):e352-e360. doi:10.1016/j.clml.2020.01.017